{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05469178",
            "orgStudyIdInfo": {
                "id": "BGBC016"
            },
            "secondaryIdInfos": [
                {
                    "id": "2019-003806-28",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "BerGenBio ASA",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer",
            "officialTitle": "Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-investigate-the-safety-tolerability-and-preliminary-anti-tumor-activity-of-bemcentinib-in-combination-with-pembrolizumab-plus-pemetrexed-and-carboplatin-in-adult-participants-with-untreated-non-squamous-non-small-cell-lung-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-12-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-19",
            "studyFirstSubmitQcDate": "2022-07-19",
            "studyFirstPostDateStruct": {
                "date": "2022-07-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-06",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BerGenBio ASA",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L) treatment in participants with locally advanced (Stage IIIb/IIIC) or metastatic (Stage IV) non-squamous NSCLC with no actionable mutations and to determine the anti-tumor activity of the combination of bemcentinib with CIT when administered as 1L treatment in participants with locally advanced (Stage IIIb/IIIc) or metastatic (Stage IV) non-squamous NSCLC with serine/threonine kinase 11 (STK11) mutation and no actionable mutations."
        },
        "conditionsModule": {
            "conditions": [
                "Carcinoma, Non-Small-Cell Lung"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 64,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1b Cohort 1: Bemcentinib Dose 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 1 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).",
                    "interventionNames": [
                        "Drug: Bemcentinib",
                        "Drug: Pembrolizumab",
                        "Drug: Pemetrexed",
                        "Drug: Carboplatin"
                    ]
                },
                {
                    "label": "Phase 1b Cohort 2: Bemcentinib Dose 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 2 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).",
                    "interventionNames": [
                        "Drug: Bemcentinib",
                        "Drug: Pembrolizumab",
                        "Drug: Pemetrexed",
                        "Drug: Carboplatin"
                    ]
                },
                {
                    "label": "Phase 1b Cohort 3: Bemcentinib Dose 3",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 3 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).",
                    "interventionNames": [
                        "Drug: Bemcentinib",
                        "Drug: Pembrolizumab",
                        "Drug: Pemetrexed",
                        "Drug: Carboplatin"
                    ]
                },
                {
                    "label": "Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with previously untreated advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC having a serine/threonine kinase 11 (STK11) mutation as identified by Next Generation Sequencing (NGS) and without actionable mutations will receive bemcentinib, at RP2D identified in Phase 1b, once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).",
                    "interventionNames": [
                        "Drug: Bemcentinib",
                        "Drug: Pembrolizumab",
                        "Drug: Pemetrexed",
                        "Drug: Carboplatin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bemcentinib",
                    "description": "Bemcentinib capsules will be administered orally.",
                    "armGroupLabels": [
                        "Phase 1b Cohort 1: Bemcentinib Dose 1",
                        "Phase 1b Cohort 2: Bemcentinib Dose 2",
                        "Phase 1b Cohort 3: Bemcentinib Dose 3",
                        "Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab will be administered as an IV infusion as part of CIT every 3 weeks.",
                    "armGroupLabels": [
                        "Phase 1b Cohort 1: Bemcentinib Dose 1",
                        "Phase 1b Cohort 2: Bemcentinib Dose 2",
                        "Phase 1b Cohort 3: Bemcentinib Dose 3",
                        "Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pemetrexed",
                    "description": "Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.",
                    "armGroupLabels": [
                        "Phase 1b Cohort 1: Bemcentinib Dose 1",
                        "Phase 1b Cohort 2: Bemcentinib Dose 2",
                        "Phase 1b Cohort 3: Bemcentinib Dose 3",
                        "Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks.",
                    "armGroupLabels": [
                        "Phase 1b Cohort 1: Bemcentinib Dose 1",
                        "Phase 1b Cohort 2: Bemcentinib Dose 2",
                        "Phase 1b Cohort 3: Bemcentinib Dose 3",
                        "Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1b: Number of Participants with Dose Limiting Toxicity (DLT)",
                    "description": "DLT will be graded using NCI CTCAE Version 5.0 based on the Investigator assessment.",
                    "timeFrame": "Cycle 1 (the first 21 days of treatment)"
                },
                {
                    "measure": "Phase 2a: Objective Response Rate (ORR) at 6 Months",
                    "description": "ORR is defined as percentage of participants with complete response and partial response per RECIST 1.1.",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Phase 2a: Objective Response Rate (ORR) at 12 Months",
                    "description": "ORR is defined as percentage of participants with complete response and partial response per RECIST 1.1.",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Main Inclusion Criteria:\n\n* Histologically-confirmed or cytologically confirmed diagnosis of advanced (Stage IIIb/IIIc) or metastatic (Stage IV) (AJCC Edition 8) non-squamous NSCLC not amenable to curative therapy, irrespective of PD-L1 status and without actionable mutations (Phase 1b)\n* Histologically-confirmed or cytologically confirmed diagnosis of stage of advanced (Stage IIIb/IIIC) or metastatic (Stage IV) (AJCC, Edition 8) non-squamous NSCLC with STK11 mutation, not amenable to curative therapy, irrespective of PD-L1 status and without actionable mutations (phase 2a)\n* Have not received prior systemic treatment for their advanced/metastatic NSCLC\n* Have measurable disease per RECIST 1.1 as assessed by the investigator\n\nMain Exclusion Criteria:\n\n* Has received any prior chemotherapy or biological therapy for locally advanced (Stage IIIb/IIIc) or metastatic (Stage IV) adenocarcinoma of the lung\n* Has an EGFR Exon 19 Deletion or L858R mutation, EGFR S768I, L861Q, and/or G719X mutations, ALK gene rearrangement, ROS1 rearrangement, rearranged during transfection (RET) rearrangement, NRTK1/2/3, gene fusion, BRAF V600E mutation, METex14 Skipping Mutation\n* Received radiation therapy within 2 weeks prior to starting study treatment or has not recovered (i.e. \\<=Grade 1 at baseline) from AEs due to a previous radiation therapy\n* Major surgery within 28 days prior to start of study treatment and failure to have recovered adequately from the complications of the surgery/intervention prior to the first dose of study treatment",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BerGenBio Clinical Team",
                    "role": "CONTACT",
                    "phone": "+47 559 61 159",
                    "email": "trialsites@bergenbio.com"
                }
            ],
            "locations": [
                {
                    "facility": "Mount Sinai Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Miami Beach",
                    "state": "Florida",
                    "zip": "33140",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.79065,
                        "lon": -80.13005
                    }
                },
                {
                    "facility": "Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21201",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Icahn School of Medicine at Mount Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Tennessee Oncology PLLC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "UT Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Individual participant data that underlie the results reported in the article, after deidentification \\[text, tables, figures and appendices\\]."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "D000068437",
                    "term": "Pemetrexed"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000005493",
                    "term": "Folic Acid Antagonists"
                },
                {
                    "id": "D000019384",
                    "term": "Nucleic Acid Synthesis Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M264",
                    "name": "Pemetrexed",
                    "asFound": "Target",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M17546",
                    "name": "Vitamin B Complex",
                    "relevance": "LOW"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M8619",
                    "name": "Folic Acid Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "T18",
                    "name": "Serine",
                    "relevance": "LOW"
                },
                {
                    "id": "T20",
                    "name": "Threonine",
                    "relevance": "LOW"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T447",
                    "name": "Folinic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "relevance": "LOW"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}